When knee pain becomes persistent, injections often sound appealing.
Patients may think:
- “Maybe this will fix it.”
- “If I can just get the right injection, I’ll be sorted.”
- “This sounds easier than rehabilitation.”
- “Surely the latest biologic option must be the answer.”
This is understandable.
Injections are widely discussed in knee osteoarthritis care.
But every intervention has limitations.
Understanding those limitations helps patients make more realistic, informed decisions.
First Principle: Injections Solve Different Problems
One common misconception:
“An injection is an injection.”
Not true.
Different injections target different concepts.
Examples:
Corticosteroids:
- symptom control / inflammatory modulation
Hyaluronic acid:
- viscosupplementation rationale
PRP:
- biologic signalling rationale
APS:
- broader biologic protein modulation rationale
These are not interchangeable.
And none automatically “fix arthritis.”
Limitation 1: Injections Do Not Cure Osteoarthritis
This is the most important clarification.
Most injection pathways are discussed for:
- symptom management
- selected functional support
- symptom modulation
- adjunctive care
They do not reliably:
- regrow cartilage
- reverse structural degeneration
- restore a normal joint
- permanently remove symptoms
Patients often overestimate what injections can realistically do.
The American College of Rheumatology includes injections in selected management pathways, but not as structural cures.
Limitation 2: Response Is Variable
A major practical reality:
different patients respond differently.
Outcomes may vary depending on:
- diagnosis accuracy
- osteoarthritis severity
- symptom drivers
- inflammatory contribution
- overlapping pathology
- procedural factors
- expectations
A treatment that helps one patient may not help another.
Limitation 3: Wrong Diagnosis = Wrong Intervention
An injection cannot solve the wrong problem.
Examples:
If the actual issue involves:
- inflammatory arthritis
- meniscal pathology
- tendon overload
- referred pain
- mixed diagnoses
then injection expectations may be misaligned.
Diagnostic clarity matters.
Limitation 4: Symptom Relief May Be Temporary
Patients often ask:
“How long does it last?”
This varies.
Temporary benefit may occur.
Symptoms may recur.
Durability is not predictable for every patient.
The practical question becomes:
“What happens if symptoms return?”
Limitation 5: Injections Do Not Replace Rehabilitation
A common misconception:
“If I get symptom relief, I don’t need to address anything else.”
Not necessarily.
Pain may be only part of the problem.
Functional contributors may still exist:
- weakness
- poor endurance
- gait inefficiency
- stair intolerance
- deconditioning
- weight-related loading issues
Symptom modulation does not automatically solve functional limitations.
Limitation 6: Imaging Findings May Mislead Expectations
Patients sometimes pursue injections based purely on scan findings.
But imaging abnormalities do not always explain symptoms.
The Osteoarthritis Research Society International (OARSI) supports individualised management decisions rather than treatment decisions based solely on imaging appearances.
The presence of abnormalities does not automatically mean injection is the correct answer.
Limitation 7: Newer Does Not Automatically Mean Better
Patients often assume:
“Biologic” = superior
or
“newer” = more effective
This is not automatically true.
Evidence maturity differs significantly between interventions.
Marketing language can create unrealistic assumptions.
Limitation 8: Cost Matters
Some interventions involve substantial cost.
Patients should reasonably consider:
- realistic evidence strength
- expected goals
- uncertainty
- alternatives
- broader care planning
Cost alone should not determine care—but practical decision-making matters.
Limitation 9: Shared Decision-Making Is Still Needed
No intervention exists in isolation.
Decision-making should consider:
- diagnosis
- symptom goals
- function
- alternatives
- expectations
- broader health context
The National Institute for Health and Care Excellence (NICE) supports broader osteoarthritis management planning rather than simplistic intervention-driven thinking.
Common Misunderstandings
“The right injection fixes arthritis.”
No.
That is an unrealistic expectation.
“If it helps once, I am cured.”
Not necessarily.
Durability varies.
“Biologic injections must be better.”
Not automatically.
Evidence maturity differs.
“Injections replace exercise or rehabilitation.”
No.
Not in a broad functional sense.
What This Means For Patients
Useful practical questions include:
- What exactly are we trying to treat?
- Is the diagnosis clear?
- What are realistic expectations?
- Is this symptom control or structural treatment?
- What happens if benefit is temporary?
- What alternatives exist?
The better question is:
“Does this intervention realistically fit the actual problem I have?”
Practical Decision-Making Considerations
Considerations may include:
- diagnosis confidence
- symptom burden
- functional limitations
- expectations
- cost sensitivity
- alternative strategies
- broader management plan
- shared decision-making
Based on over 20 years of clinical practice, Dr Terence Tan, founder of The Pain Relief Clinic Singapore, notes that patients sometimes become focused on finding the “best injection,” when the more clinically useful discussion is whether injection-based treatment meaningfully addresses the true driver of their symptoms.
When Further Assessment May Matter
Further review may be particularly important when:
- diagnosis remains uncertain
- symptoms behave atypically
- swelling is unusual
- treatment repeatedly fails
- expectations appear unrealistic
- overlapping pathology is likely
Frequently Asked Questions
Do injections cure arthritis?
No.
They do not reverse structural osteoarthritis.
Are injections always temporary?
Response varies, but durability is not guaranteed.
Can injections replace rehabilitation?
No.
Functional management may still be necessary.
Is the newest injection automatically best?
No.
Evidence maturity differs.
What if injections fail?
Diagnosis and broader management may need reassessment.
Should cost be considered?
Yes.
Practical decision-making includes cost-awareness.
Is diagnosis important before injection?
Absolutely.
About the contributor
Dr Terence Tan is a Singapore licensed medical doctor with over 20 years of clinical practice and founder of The Pain Relief Clinic Singapore (https://painrelief.com.sg).
Medical Disclaimer
This article is for educational purposes only and does not constitute personalised medical advice, diagnosis, or treatment recommendations. Individual medical decisions should be made in consultation with an appropriately licensed healthcare professional.
Contact us on Whatsapp